IONS IONIS PHARMACEUTICALS INC Company Mergers 8-K Filing 2025 - License Agreement On March 11, 2025, Ionis Pharmaceuticals announced a license agreement with Ono Pharmaceutical for exclusive global rights to develop and commercialize sapablursen, a treatment for polycythemia vera.Get access to all SEC 8-K filings of the IONIS PHARMACEUTICALS INC